d-Wise signs another Blur enterprise software license with a Global Top-10 Pharmaceutical Company, for clinical trial de-identification

Share Article

Life Science technology leader d-Wise continues as leading worldwide individual participant data (IPD) de-identification software provider

de-identification software

The industry-leading solution for delivering de-identified clinical trial data and protecting patient privacy.

We fully expect that demand will accelerate as more and more customers discover how easy it is de-identify data and make it available for secondary use

d-Wise, a leading life science and healthcare technology solutions provider, announced today that they have signed another enterprise license agreement with a Top-10 Pharmaceutical company for their industry leading clinical trial de-identification software solution – Blur. The signing highlights d-Wise’s leadership role and continued success in delivering de-identification software and services to the biotechnology and pharmaceutical marketplace. AstraZeneca, d-Wise’s first Blur enterprise customer, is now using the solution in production, and d-Wise is actively engaged in multiple consulting projects across the industry regarding de-identification as it relates to both internal and external data sharing initiatives.

The Blur de-identification solution is specifically designed to address patient privacy and support clinical data transparency and sharing initiatives. Blur delivers high performance, application-driven, data de-identification to safeguard patient privacy while reducing the overall costs associated with the de-identification process. The solution has integrated workflow and controls, learned intelligence, and accommodates established as well as emerging de-identification rules. d-Wise continues to rapidly innovate, extending Blur’s capabilities since its initial launch in June 2015.

“d-Wise is excited to have already signed another enterprise software agreement for Blur. We fully expect that demand will accelerate as more and more customers discover how easy it is de-identify data and make it available for secondary use”, stated John Leveille, CEO at d-Wise. “Many companies talk about developing impactful software solutions for clinical research. d-Wise is delivering those solutions today.”

Biopharmaceutical companies have been anonymizing data on a small scale for years, but the era of clinical trial data transparency and sharing initiatives has changed the rules. The need to share clinical trial data with external researchers and internal planning, modeling and exploration teams has never been greater. As data sharing needs accelerate in terms of volume and urgency, the old ways of delivering anonymized data are no longer practical. Blur was developed by pharmaceutical industry experts and represents the most modern approach to patient-level data de-identification available today. The solution requires dramatically less Information Technology support than alternative scripting tools, while bringing scalability to the clinical trials de-identification process.

Blur is easily deployed through a simple browser interface, and incorporates a wide variety of clinical trials and healthcare de-identification rules that can be customized to individual projects. The availability of a point-and-click interface, instead of a programming interface, means that Blur can be used by a broad set of users. This provides considerably more flexibility than the current approaches being used today.

To learn more about d-Wise’s de-identification solution, please visit http://www.d-wise.com/blur

About d-Wise

d-Wise - http://www.d-wise.com is a technology leader with the expertise to empower world-class life science and healthcare organizations to resolve their business optimization challenges, helping them rapidly harness and leverage data, systems and processes to gain competitive advantage.

The d-Wise Life Sciences Practice has been providing clinical advisory and modernization services to our clients for over a decade. d-Wise consultants work with Life Science clients to adopt a progressive and comprehensive approach to modernizing clinical trial solutions and processes. d-Wise helps identify existing business problems – systems, processes, architecture, etc. – that inhibit your ability to achieve your clinical research goals. d-Wise enables organizations to reach those goals by modernizing software and solutions, business processes, and infrastructure. They tailor all solutions to meet individual client needs and deliver data integration, data warehousing and standards solutions within highly-regulated industries with expertise rooted in extensive domain knowledge of SAS software, clinical drug development and clinical data standards like CDISC. The company’s end-to-end expertise and assessment services encompass business process and change management; data and metadata-driven strategies; and vendor-agnostic infrastructure and technology assessments.

Within healthcare, d-Wise helps organizations develop an analytic vision, and integrate and streamline data operations for rapid deployment of visual intelligence solutions and advanced analytic models. The company is well known for their expertise and capability to implement advanced analytic solutions that improve operations, lower costs, improve health outcomes quality and facilitate executive decision-making. d-Wise has a broad range of experience that includes data optimization for actuarial, quality, medical-management, and operational functions, as well as support for IT and data organizations looking to implement best practices.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Keith W. Ward, Director, Global Marketing
+1 (919) 334-6095
Email >
Visit website